/PRNewswire/ The myopia and presbyopia treatment market size is expected to increase by USD 7.94 billion, at a CAGR of 8.09% from 2022 to 2027. Download a.
Vision Care Group CEO Masayo Takahashi led the world s first clinical study of a retinal cell transplant derived from induced pluripotent stem cells (iPS cells) in 2014 when she led the Laboratory for Retinal Regeneration at Japan’s Riken Center for Biosystems Dynamics Research. In 2019, she founded Vision Care and subsequently founded two subsidiary companies dedicated to developing cell and gene therapies.
/PRNewswire/ The myopia and presbyopia treatment market size is expected to grow by USD 7.94 billion from 2022 to 2027. In addition, the momentum of the.
/PRNewswire/ Vision Care Group and ThinkCyte today announced a research partnership aimed at advancing cell therapy in retinal disease. The partnership.